CME Presentations

CIDP Guidelines



  • Jeffrey Allen, MD

    Jeffrey Allen, MD

    Jeffrey Allen, MD

    Associate Professor, Department of Neurology

    Jeffrey Allen, MD, is assistant professor in the Department of Neurology at the University of Minnesota, Minneapolis and adjunct faculty at Northwestern University in Chicago, Illinois. His primary clinical and academic interests are inflammatory neuropathies, including Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). Dr Allen uses various studies to improve techniques currently used to diagnose inflammatory neuropathy and to identify new and improved treatment methods, including investigating new medications and improving how standard medications are utilized. He is a member of the GBS/CIDP Foundation International Global Medical Advisory Board and on the board of the Inflammatory Neuropathy Consortium (INC).
  • Thomas Harbo, MD, PhD

    Thomas Harbo, MD, PhD

    Thomas Harbo, MD, PhD

    Neuromuscular Specialist

    Thomas Harbo, MD, PhD, is a neuromuscular specialist at Aarhus University Hospital (AUH) in Aarhus, Denmark, as well as a certified Centre of Excellence by the GBS|CIDP Foundation International. In addition, Dr. Harbo is an Associate Professor and Senior Consultant at the Department of Neurology at AUH and Institute of Clinical Medicine at Aarhus University. His clinical and academic interests are focused on acute and chronic inflammatory neuropathies including Guillian-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). Dr. Harbo’s research has helped establish the role of subcutaneous immunoglobulin (SCIG) in the treatment of MMN and CIDP.
  • Lisa Butler

    Lisa Butler

    Lisa Butler

    Executive Director

    Lisa Butler is the executive director of the GBS/CIDP Foundation International in Narberth, Pennsylvania. Ms Butler has a 10-year career in marketing and event planning for nonprofit organizations. Before assuming her current position as executive director, she managed the Foundation’s marketing and development programs, and was recognized by Patient Services, Inc. (PSI) with the 2016 Extraordinary Support Award. Ms Butler first of learned of the Foundation in 1992 (prior to joining the staff in 1993) when her father-in-law was diagnosed with Guillain-Barre syndrome (GBS).Ten years later, her son, Stuart, was diagnosed with GBS. Following Stuart’s recovery, she became the parent liaison for the Foundation for “parents with children diagnosed with GBS”.

CME Information

Global Logo PQH Logo

From Diagnosis to Treatment: Patient-Centered Care with the New CIDP Guidelines

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the GBS/CIDP Foundation


This activity is supported by an educational grant from Grifols and CSL Behring.


This activity was released on January 31, 2023 and is valid until January 31, 2024. Requests for credit must be made no later than January 31, 2024


The target audiences for the proposed HCP activity are community neurologists, neuromuscular specialists, immunologists, PCPs, hospitalists, emergency physicians, APNs, RNs, pharmacists.


Differentiating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from other immune-mediated inflammatory neuropathies can be challenging for clinicians. Misdiagnoses are common and can lead to poor outcomes for patients. However, newly revised guidelines for CIDP offer an opportunity to address barriers to accurate diagnoses and appropriate treatments.

Join an expert panel of neurologists and representatives from the GBS|CIDP Foundation International to discuss disease aspects/variants, simplify accurate diagnoses, and offer evidence-based guidance on treatment options and selections. Panelists will cover the place of imaging technologies in diagnosis, recognition of CIDP based on symptoms, and testing recommendations in the 2021 guidelines. Clinicians will leave the activity better able to work with their patients to individualize treatments and incorporate emerging agents and immunoglobulin formulations as they are approved.

Do you have patients with CIDP who could benefit from education on the early symptoms and signs for this condition, along with comparisons of available treatment options? Direct your patients to to access the activity, “You Have CIDP…Now What?”


After completing this activity, the participant should be better able to:
  • Integrate the 2021 European Academy of Neurology/Peripheral Nerve Society guidelines into the diagnosis and treatment of CIDP
  • Summarize how new diagnostic criteria and use of imaging technology will improve the diagnosis of CIDP and its variants
  • Formulate individualized treatment plans with the patient based on updated recommendations, patients’ quality of life, and measures of disability and impairment
  • Summarize rationale for the need and data to date with new approaches to the treatment of CIDP, including new immunoglobulin formulations and FcRn receptor-targeted agents


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Dr. Jeffrey Allen
Associate Professor
University of Minnesota
Co-Owner/Founder: Argenx, Alexion, Anylym, CSL behring, Grifols, Pfizer, Jannsen, Takeda, Immunovant, Immupharma
Consulting Fee: Argenx, Alexion, CSL behring, Takeda
Honoraria: Argenx, Anylym, CSL behring
Dr. Lisa Butler
Executive Director
GBS/CIDP Foundation International
Nothing to disclose
Dr. Thomas Harbo
Associate Professor, Depart of Neurology
Aarhus University Hospital
Nothing to disclose

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Name of Planner or Manager Reported Financial Relationship
Carole Drexel Nothing to disclose
Caroline Laurendeau Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact at 877-394-1306 or at